BSF Enterprise says well positioned for growth as interim loss narrows
BSF Enterprise PLC on Wednesday announced a narrowed loss as it remains dedicated to advancing its portfolio, which focuses on sustainable tissue-engineered materials.
The London-based biotech company is the owner of companies including 3D Bio-Tissues, a pioneer of lab-grown tissues, as well as the corneal replacement company Kerato.
The company said pretax loss narrowed to £793,963 in the six months to March 31, from £864,775 a year prior.
Revenue fell 62% to £20,559 from £54,295. Grant income jumped to £67,823 from £3,779.
Cost of sales came down 81% to £5,065 from £25,997.
Looking ahead, BSF Enterprise said: ‘BSF Enterprise remains dedicated to advancing its portfolio of sustainable tissue-engineered materials and strategic collaborations. With significant progress in lab-grown leather commercialisation, partnerships with industry leaders, and successful financing initiatives completed in 2025, the group is well-positioned for continued growth, innovation, and value creation in the year ahead.’
BSF Enterprise shares were 0.7% higher at 2.27 pence each on Wednesday afternoon in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.